Clinical Trials
38 results for Prostate Cancer
Prospective Evaluation of CyberKnife® as Monotherapy or Boost Stereotactic Body Radiotherapy for Intermediate or High Risk Localized Prostate Cancer
- Condition: Prostate Adenocarcinoma
- Intervention: Radiation: CyberKnife, Other: Androgen Deprivation Therapy (ADT), Radiation: Intensity Modulated radiation therapy (IMRT)
- Study ID: NCT01985828
A Pilot Study of Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (13C) to Detect High Grade Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Pyruvate (13C)
- Study ID: NCT02526368
The UCLA ASCAP Project is an Observational, Longitudinal, and Open-ended Study Aimed at Establishing a Structured Program of Non-interventional Follow-up for Localized Prostate Cancer.
- Condition: Prostate Cancer
- Intervention: Other: Active surveillance
- Study ID: NCT00949819
Prospective Evaluation of CyberKnife Stereotactic Body Radiotherapy for Localized Prostate Cancer: Risk Stratified Monotherapy Versus Boost
- Condition: Prostate Cancer
- Intervention:
- Study ID: NCT02016248
Perioperative Pelvic Floor Muscle Training May Improve Recovery of Continence in Men With Localized Prostate Cancer Undergoing Robot-Assisted Radical Prostatectomy
- Condition: Prostate Cancer, Urinary Incontinence, Pelvic Floor Physical Therapy
- Intervention:
- Study ID: NCT02558946
Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial
- Condition: Prostatic Neoplasms
- Intervention: Procedure: Prostatectomy/Surgery, Other: Radiotherapy with adjuvant androgen deprivation therapy
- Study ID: NCT02102477
Focal Low Dose Rate ( LDR) Brachytherapy: Hemi-ablative Treatment With LDR for Patients With Low and Low-tier Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy
- Study ID: NCT02643511
Safety and Early Efficacy of Radical Prostatectomy for Newly Diagnosed Very High Risk Locally Advanced and Oligometastatic Prostate Cancer - a Prospective Single Center Phase I/II Study
- Condition: Locally Advanced and Metastatic Prostate Cancer
- Intervention: Procedure: Radical prostatectomy
- Study ID: NCT02971358
Phase III Study of Image Guided Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Adenocarcinoma of the Prostate
- Condition: Prostate Cancer
- Intervention: Radiation: Radiation, Drug: Androgen Suppression Therapy
- Study ID: NCT01492972
A Randomized, Double-Blind, Placebo-Controlled Trial of Metformin in Reducing Progression Among Men on Expectant Management for Low Risk Prostate Cancer: The MAST (Metformin Active Surveillance Trial) Study
- Condition: Prostate Cancer
- Intervention: Drug: Metformin, Drug: Placebo
- Study ID: NCT01864096
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
- Condition: Breast Cancer, Bladder Cancer, Kidney Cancer, Colon Cancer, Prostate Cancer, Lung Cancer, Ovarian Cancer
- Intervention: Genetic: PCR/PCR/LDR Strategy
- Study ID: NCT00579514
Collection of Blood From Patients With Prostate Cancer
- Condition: Prostatic Neoplasms
- Study ID: NCT00923221
Canary Prostate Active Surveillance Study
- Condition: Prostatic Neoplasms
- Study ID: NCT00756665
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
- Study ID: NCT00588185
A Pilot Study of High Dose Rate Brachytherapy in The Radiation Oncology Branch
- Condition: Cervical Cancer, Endometrial Cancer, Esophageal Cancer, Prostate Cancer, Biliary Cancer
- Intervention: Radiation: Brachytherapy
- Study ID: NCT00924027
Hereditary Leiomyomatosis Renal Cell Cancer (HLRCC): Identification of the Disease Gene and Characterization of the Predisposition to Renal Cancer
- Condition: Renal Tumor Histology, Cutaneous Leiomyomatosis, Kidney Cancer
- Study ID: NCT00050752
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease
- Condition: Malignant Neoplasms, Hereditary Neoplastic Syndromes, Kidney Cancer, Renal Cancer
- Study ID: NCT00026884
A Phase III Randomized Trial of MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
- Condition: Prostate Cancer, Prostate Adenocarcinoma
- Intervention: Radiation: Standard Salvage Radiation Treatment (SSRT), Radiation: Mapped Tumor Salvage RT (MTSRT), Behavioral: Expanded Prostate Cancer Index Composite-SF12, Behavioral: Memory Anxiety Scale for Prostate Cancer patients, Behavioral: International Prostate Symptom Score (IPSS)
- Study ID: NCT01411345
Postoperative or Salvage Radiotherapy for Node Negative Prostate Cancer Following Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Radiation: IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE, Radiation: Proton (prostate bed) to 70.2 CGE, Radiation: IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE, Radiation: Proton to 66.6 CGE
- Study ID: NCT00969111
A Randomized Trial of Modifications to Radical Prostatectomy
- Condition: Prostate Cancer
- Intervention: Procedure: Lymph node template, Procedure: Transverse versus vertical closure, Drug: antibiotic prophylaxis
- Study ID: NCT01407263
Collection of Blood From Patients With Cancer for Analysis of Genetic Differences in Drug Disposition
- Condition: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
- Study ID: NCT01441089
Biospecimen Acquisition From Human Subjects
- Condition: Prostate Cancer, Breast Cancer, Colon Cancer, Lung Cancer, Liver Cancer
- Intervention:
- Study ID: NCT00034216
Carbon Ion Radiotherapy for the Treatment of Localized Prostate Cancer
- Condition: Prostate Carcinoma
- Intervention:
- Study ID: NCT02739659
Phase I/II Study of PROSTVAC in Combination With Nivolumab and / or Ipilimumab in Men With Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Biological: PROSTVAC-V/F, Drug: Nivolumab, Drug: Ipilimumab
- Study ID: NCT02933255
HDR Monotherapy for Prostate Cancer: A Feasibility Study of Focal Radiotherapy Yields
- Condition: Prostate Cancer
- Intervention: Radiation: targeted focal HDR brachytherapy, Radiation: Whole-gland HDR Brachytherapy
- Study ID: NCT02918253
Phase II Study: [18F]DCFPyL PET/MRI for Personalizing Prostate Cancer Subclinical Metastatic Ablative MR-guided Radiotherapy (MRgRT)
- Condition: Post Prostatectomy
- Intervention: Diagnostic Test: [18F]DCFPyL PET/MRI scan, Radiation: Stereotactic Ablative Radiotherapy
- Study ID: NCT03160794
Diagnosing Clinically Significant Prostate Cancer in African American and White Men Phase II, Randomized Clinical Trial, Multi-center, MR-Guided vs. 12-core Systematic Random Biopsy, Localized Prostate Cancer
- Condition: Health Status Unknown, PSA Progression
- Intervention: Procedure: Biopsy of Prostate, Other: Laboratory Biomarker Analysis, Diagnostic Test: Magnetic Resonance Imaging, Diagnostic Test: MRI Ultrasound Fusion Guided Biopsy
- Study ID: NCT03234556
PHASE I STUDY OF PSMA-TGFβRDN CAR MODIFIED T CELLS IN PATIENTS WITH ADVANCED CASTRATE RESISTANT PROSTATE CANCER
- Condition: Prostate Cancer
- Intervention:
- Study ID: NCT03089203
Cystoprostatectomy Versus Radiotherapy Combined With Androgen Deprivation Therapy for the Treatment of Clinical T4 Prostate Cancer With Bladder Invasion: a Multicentre, Prospective, Open, Randomized Clinical Trial
- Condition: Prostate Cancer
- Intervention: Procedure: Cystoprostatectomy, Radiation: external beam radiotherapy
- Study ID: NCT03482089
Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Stereotactic Body Radiation Therapy (SBRT)
- Condition: Prostate Cancer, Localized Malignant Neoplasm
- Intervention: Radiation: Stereotactic Body Radiation Therapy (SBRT)
- Study ID: NCT01766492
Phase II Study of Neoadjuvant Pembrolizumab Plus Intensive Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Drug: Pembrolizumab, Drug: Enzalutamide
- Study ID: NCT03753243
Phase 2, Multicenter, Prospective Cohort Study, Estimating the Efficacy of Focused HIFU Therapy in Patients With Localized Intermediate Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies, Biological: blood test, Biological: urine test
- Study ID: NCT03568188
A Randomized Pilot Study Comparing High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy in Localized Prostate Cancer
- Condition: Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8
- Intervention: Radiation: High-Dose Rate Brachytherapy, Other: Quality-of-Life Assessment, Other: Questionnaire Administration, Procedure: Stereotactic Ablative Radiotherapy
- Study ID: NCT04253483
Hypofractionated Radiosurgery for Localised Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Radiation: Hypofractionated Radiosurgery
- Study ID: NCT03795337
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Apalutamide in Subjects With High-risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
- Condition: Prostatic Neoplasms
- Intervention: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT), Drug: Placebo
- Study ID: NCT03767244
Phase 3, Multicenter, Randomized Study, Evaluating the Efficacy and Tolerability of Focused HIFU Therapy Compared to Active Surveillance in Patients With Significant Low Risk Prostate Cancer
- Condition: Prostate Cancer
- Intervention: Procedure: treatment with focal HIFU, Biological: PSA dosage, Device: MRI, Other: Questionnaires, Procedure: Prostatic biopsies
- Study ID: NCT03531099
Protocol for the Development of a Machine Learning Model for Prostate Cancer Treatment Planning
- Condition: Prostate Cancer, Artificial Intelligence, Radiotherapy
- Study ID: NCT04441775
Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)
- Condition: Metastatic Malignant Neoplasm in the Bone, Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Study ID: NCT04513717